全文获取类型
收费全文 | 21185篇 |
免费 | 2163篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 130篇 |
儿科学 | 573篇 |
妇产科学 | 589篇 |
基础医学 | 3373篇 |
口腔科学 | 318篇 |
临床医学 | 2764篇 |
内科学 | 4140篇 |
皮肤病学 | 295篇 |
神经病学 | 1631篇 |
特种医学 | 870篇 |
外科学 | 2470篇 |
综合类 | 424篇 |
一般理论 | 29篇 |
预防医学 | 2442篇 |
眼科学 | 452篇 |
药学 | 1598篇 |
中国医学 | 22篇 |
肿瘤学 | 1269篇 |
出版年
2023年 | 156篇 |
2022年 | 189篇 |
2021年 | 448篇 |
2020年 | 303篇 |
2019年 | 465篇 |
2018年 | 539篇 |
2017年 | 402篇 |
2016年 | 427篇 |
2015年 | 474篇 |
2014年 | 657篇 |
2013年 | 912篇 |
2012年 | 1287篇 |
2011年 | 1314篇 |
2010年 | 762篇 |
2009年 | 639篇 |
2008年 | 1064篇 |
2007年 | 1142篇 |
2006年 | 1095篇 |
2005年 | 1059篇 |
2004年 | 984篇 |
2003年 | 925篇 |
2002年 | 802篇 |
2001年 | 481篇 |
2000年 | 456篇 |
1999年 | 458篇 |
1998年 | 245篇 |
1997年 | 204篇 |
1996年 | 212篇 |
1995年 | 221篇 |
1994年 | 191篇 |
1993年 | 202篇 |
1992年 | 349篇 |
1991年 | 355篇 |
1990年 | 288篇 |
1989年 | 294篇 |
1988年 | 253篇 |
1987年 | 270篇 |
1986年 | 263篇 |
1985年 | 284篇 |
1984年 | 237篇 |
1983年 | 181篇 |
1982年 | 137篇 |
1981年 | 119篇 |
1980年 | 100篇 |
1979年 | 160篇 |
1978年 | 132篇 |
1977年 | 102篇 |
1976年 | 99篇 |
1974年 | 113篇 |
1973年 | 112篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
4.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
5.
6.
7.
8.
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas 总被引:1,自引:0,他引:1
H. von Holst E. Knochenhauer H. Blomgren V. P. Collins L. Ehn M. Lindquist G. Norén C. Peterson 《Acta neurochirurgica》1990,104(1-2):13-16
Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue. 相似文献
9.
W J Scott C A Duggan C M Schreiner M D Collins 《Toxicology and applied pharmacology》1990,103(2):238-254
The effects of acetazolamide on the developing rodent limb bud were postulated to result from a reduction of intracellular pH (pHi). Embryonic intracellular pH was calculated from transplacental distribution of the weak acid, 5,5'-dimethyloxazolidine-2,4-dione, in teratogenically sensitive (C57BL/6) and resistant (SWV) inbred mice. pHi was reduced by acetazolamide treatment in C57 embryos and limb buds but not in SWV samples. Acetazolamide teratogenesis can be exacerbated by coadministration of amiloride, presumably through inhibition of Na+/H+ exchange attributable to the latter agent. pHi reduction after such treatment was more profound than after acetazolamide alone, providing further support for the central hypothesis. pH was also reduced in other embryonic (embryo plasma) and extraembryonic compartments (exocoelomic fluid, amniotic fluid). pH changes in these compartments could also lead or contribute to abnormal development. 相似文献
10.